Intuitive Surgical: When a 37% Drawdown Meets a Wall of Analyst Conviction

Intuitive Surgical shares fell 37% despite strong Q2 results, as FDA approval for J&J's Ottava sparks selloff. Analysts see 37% upside, UBS upgrades to Buy.

The gap between what the stock market is saying about Intuitive Surgical and what the analysts covering it believe has rarely been this wide. Shares of the robotic surgery pioneer have shed roughly 37 percent since the start of the year, yet the average price target among Wall Street analysts implies upside of nearly 37 percent from current levels. That disconnect — a market pricing in competitive doom against a research community still largely bullish — sits at the heart of the current debate over the company's trajectory.

The FDA Approval That Shook the Stock

The immediate trigger for the latest leg of selling arrived in late July, when the FDA granted de-novo clearance to Johnson & Johnson's Ottava system. It marked the first time Intuitive faces a credible domestic challenger in the multi-port robotics market. The market response was swift: on July 23, the stock touched its yearly low of €289.05 in Frankfurt trading.

Since that trough, the share price has clawed back 3.59 percent to €307.45. Modest as that recovery is, it suggests the aggressive July selling wave is losing momentum. The critical question now is whether J&J can meaningfully challenge a base of nearly 13,000 installed systems worldwide. Market observers estimate that competitors like J&J and Medtronic trail by five to ten years in training infrastructure and clinical integration. The economics of switching favor the incumbent: surgeons who complete a certain case volume on the da Vinci platform within their first 90 days remain loyal to it 90 percent of the time. That installed-base advantage makes hospital transitions costly and inconvenient — a moat Ottava will not breach overnight.

A Quarter That Beat, a Guide That Cautious

Operationally, the company continues to deliver the kind of numbers that typically support a premium valuation. Second-quarter revenue rose 19 percent to $2.89 billion, beating expectations, while adjusted earnings per share came in at $2.80, also above consensus.

The caution sits in the outlook. Management reaffirmed its full-year guidance for da Vinci procedure growth of 13.5 to 15.5 percent, but acknowledged that US growth slowed to 12 percent in the second quarter. China adds another layer of pressure, with government-directed pricing constraints and local competitors weighing on the business.

None of that, however, paints a picture of a company in crisis. The da Vinci 5 rollout continues apace — 246 units were placed in the second quarter alone, accounting for more than half of all system placements in the period. This looks less like a business in trouble and more like one navigating a cycle transition with elevated investment demands.

UBS Flips the Switch

The most notable vote of confidence came on July 28, when UBS analyst Patrick Wood upgraded the stock from "Neutral" to "Buy." Wood trimmed his price target from $550 to $500, but that adjustment came as part of a coverage handover to a new analyst rather than a change in fundamental view. The bank's core thesis: the market has punished Intuitive too harshly.

UBS identifies three concerns that have shaped the bearish narrative — softening hospital spending, decelerating growth, and intensifying competition from other robotics players — and dismisses each as overblown. The bank sees continued automation as a tailwind that should accelerate adoption of the da Vinci system, which already facilitates millions of minimally invasive procedures annually.

The upgrade landed just one day after Intuitive revised its corporate charter, changing how shareholders nominate board candidates, submit proposals, and call special meetings. Some market watchers view the tightened governance rules as a potential headwind for the undervaluation thesis, arguing that if sentiment deteriorates further, the new share registration and reduced shareholder input rights could add pressure.

The Valuation Debate That Divides Wall Street

UBS is far from alone in its optimism. According to CNN Business, 71 percent of Wall Street analysts rate the stock a "Buy." The median price target of $485 sits roughly 43 percent above current levels, with some individual targets implying upside of as much as 103 percent.

Yet the valuation metrics give the bears ammunition. Intuitive trades at a price-to-earnings multiple of 40.7 — comfortably above what analysts consider fair value at 34.5 and well above the sector average of around 29. That premium explains why the analyst community remains split: growth believers point to the automation opportunity, while valuation skeptics argue the multiple already prices in much of the anticipated recovery.

Where the Stock Stands Now

In Frankfurt, the shares closed Thursday at €305.65, down 0.92 percent on the day. That leaves the stock roughly 41 percent below its January high of €516.50 — a measure of just how deep this year's sell-off has run. The technical picture remains mixed: the stock trades well below its 50-day moving average and the long-term trend has yet to turn. But the relative strength index at 39.7 suggests the shares are closer to oversold territory than overbought, and the stabilization since the July low points to long-term investors re-entering positions.

The bull case rests on two pillars: recurring revenue makes up 85 percent of the total, and the high-margin upgrade cycle around da Vinci 5 is still in its early innings. With more than 17 million cumulative procedures completed, the structural lead provides a buffer that should keep new entrants in supporting roles rather than starring ones — at least for now. The 30-day volatility of roughly 58 percent suggests short-term nerves will persist, but the fundamental gap between market fear and analyst conviction is exactly the kind of discrepancy that tends to close over time.